Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Primary antibodies

Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908) (AB691083)

Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908)
Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908)
Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908)
Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908)
Price(USD):
Spec:
  • 50ug
  • 100ug
  • 1mg
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.AB691083
Description
Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908) (AB691083) is a mouse monoclonal antibody detecting Daratumumab in ELISA. Suitable for General.
Highlights
  • ●Affinity Purified — Minimal background and high purity for reliable results.
Species reactivityGeneral
ApplicationsELISA
Host speciesMouse
ClonalityMonoclonal
IsotypeIgG1
Clone IDSAA2908
Immunogen Daratumumab
Endotoxin level < 10EU/mg
Purity >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession CAS: 945721-28-8
Form Liquid
Storage buffer 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Background

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (Daratumumab) is a ~34 kDa protein. Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity.

1. Tohgo, A. et al. (1994) The Journal of biological chemistry 269, 28555-7. PMID: 7961800
2. Takasawa, S. et al. (1993) The Journal of biological chemistry 268, 26052-4. PMID: 8253715
3. Moreschi, I. et al. (2006) Biochemical and biophysical research communications 345, 573-80. PMID: 16690024
4. Deaglio, S. et al. (1998) Journal of immunology (Baltimore, Md. : 1950) 160, 395-402. PMID: 9551996
5. Frasca, L. et al. (2006) Blood 107, 2392-9. PMID: 16293598
6. Deaglio, S. et al. (2001) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15, 580-2. PMID: 11259373
Note For research use only.
Images
  • Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908)

    Bioactivity

    Blocks the binding of Daratumumab (Catalog No: HB691016) to CD38.

  • Anti-Daratumumab Neutralizing Recombinant Antibody (SAA2908)

    Bioactivity

    Detects Daratumumab (Catalog No: HB691016) in indirect ELISA.

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: [email protected]

Distributor list